Category: Hsp90

Data CitationsEuropean Medications Agency

Data CitationsEuropean Medications Agency. reduction in TGs (based on the efficacy of fibrates) was achieved by 88 vs 9% patients (p 0.0001). ApoC3 levels were reduced by 84% compared with a 6% increase on placebo at 3 months. In the treated group CM TGs were reduced by 83%, apoB48 by 76%, nonCHDL-cholesterol (nHDL-C) by 46%,…

Supplementary Materialspharmaceuticals-12-00033-s001

Supplementary Materialspharmaceuticals-12-00033-s001. (5-FU) (= 0.0032) treatment than parental cisplatin-sensitive cells (OE33 Cis P). Gene expression profiling identified differences at the gene level between cisplatin-sensitive and cisplatin-resistant cells, uncovering 692 genes that were significantly altered between OE33 Cis R cells and OE33 Cis P cells. OAC is an inflammatory-driven cancer, and inflammatory secretome profiling identified 18…